NCT01711541 - Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 22, 2012

Primary Completion Date

February 15, 2018

Study Completion Date

May 15, 2023

Conditions

Head and Neck Squamous Cell CarcinomaStage IVA Oropharyngeal Carcinoma AJCC v7Stage IVB Oropharyngeal Carcinoma AJCC v7

Interventions

DRUG

Carboplatin

Given IV

DRUG

Cisplatin

Given IV

DRUG

Fluorouracil

Given IV

DRUG

Hydroxyurea

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

OTHER

Placebo Administration

Given PO

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

Veliparib

Given PO

Trial Locations (5)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

60201

NorthShore University HealthSystem-Evanston Hospital, Evanston

60611

Northwestern University, Chicago

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH